Quality Control of Bacteriostatic Water | Tests, Specifications and a Release Checklist

Bacteriostatic water is a very simple product to manufacture in a sterile manufacturing facility. It is essentially preservative added to sterile water (typically 0.9% benzyl alcohol) and filled into small (multi-dose) vials. Don't be fooled by its simplicity. The product must remain sterile and preserved for a long time after initial withdrawal (due to the many punctures through the same vial) and each batch needs to be tested for this.

This article provides some insights into the typical QC tests that go into the batch of bacteriostatic water. What are typical specifications? How is preservative effectiveness shown? What practical checklist can you use for releasing a batch or reviewing a supplier's COA (Certificate of Analysis)?

1. What Makes Bacteriostatic Water Different

Sterile water for injection is for single use. Once the container is opened there is nothing to prevent growth of any microorganisms that may be introduced. With bacteriostatic water an antimicrobial preservative is added so that low levels of contamination introduced through repeated puncture can be suppressed.

This is the main difference and the focus for much of the QC:

• Every batch should have the preservative at labelled concentration
• The preservative system should work (not just be there)
• More important that container closure integrity (stopper is frequently pierced)
• Preservative and its concentration should be stated on the label

The monograph for Bacteriostatic Water for Injection in USP also sets limits the size of the container (no greater than 30ml) and also requires the name and proportion of the antimicrobial agent be stated on the label.

2. Release Tests and Typical Specifications

The common release specs for bacteriostatic water would typically include the following tests. Specific limits are always defined by the applicable pharmacopoeia and the product-registered spec.

Tests	Typical procedure	Typical acceptability criteria
Appearance	Visual examination	Clear, colorless, free of visible particles
pH	Potentiometric	4.5 - 7.0
Benzyl alcohol content	Assay by GC or HPLC	Within the range of labelled claim (e.g. 0.9% w/v)
Sterility	USP <71>/Ph.Eur. 2.6.1	No growth
Bacterial endotoxins	USP <85>/Ph. Eur. 2.6.14	NMT 0.25 EU/mL (in house limit; Ph. requirement 0.5 EU/mL)
Sub-visible particles	USP <788> Light obscuration	NMT 6000 for ≥10 micron; NMT 600 for ≥25 micron
Fill volume	Gravimetric or volumetric	Not less than label volume

A few useful points for your QC:

• Unbuffered water will drift with CO₂ uptake. Measure promptly. Record temperature.
• Some rubber stoppers may absorb benzyl alcohol through sorption over time. Trend your assays through the shelf life, not just on release.
• Validate your endotoxin testing. You need to do interference testing as the benzyl alcohol could interfere with some LAL tests. Many manufactures impose an internal release limit of 0.25 EU/ml (half the pharmacopoeial limit) to have a margin of safety throughout the shelf life.

3. Demonstration of Effectiveness of Preservative

You can see it is there by assay. You can demonstrate that it is effective by Antimicrobial Effectiveness Test (AET). This is not a test that is conducted for every batch, but usually carried out for development, stability and subsequent to any formulation or package changes.

USP <51> (category 1 - parenteral products) uses specified organisms (eg S. aureus, P. aeruginosa, E. coli, C. albicans and A.brasiliensis) to challenge the product. The requirement for bacteria is that there is a reduction of the initial count by not less than 1.0 log at 7 days; not less than a 3.0 log reduction at 14 days and no increase from day 14 to 28 days; and for yeasts and moulds no increase from initial count at 7, 14 and 28 days.

Ph.Eur. 5.1.3 sets tighter criteria for parenteral preparations. It sets a requirement of a 2 log reduction at 6 hour, a 3 log at 24 hour for bacteria (criterion A), with no recovery at 28 days. Minimum acceptable (if you can't meet A for valid reasons) is called for criterion B.

Many manufacturers will make the preservative system for their product capable of meeting the tighter criteria for the Ph.Eur. when it is marketed in more than one market.

4. Container Closure Integrity/ in-use Period

A multi-dose container is only as good as the closure system. The integrity of the container closure (CCI) should be demonstrated by an appropriate method (e.g. vacuum decay or high voltage leak detector) by using a method similar to the one outlined in USP <1207>. Considering stopper coring and resealing for repeated puncturing in development studies would be beneficial.

USP <797> provides a default 28-day beyond use for opened multiple dose containers unless otherwise specified by manufacturer. Ensure that label and in-use instructions (if any) are consistent with the supporting stability and AET data. QC/QA should ensure consistency.

5. Flow of Batch Release 

Typical flow of batch release of bacteriostatic water is summarized in the following diagram.

It is easy to miss the following points:

• If you get out-of-spec (OOS) results, formal investigation is required before any retest. In the FDA guideline on OOS results, retesting to in-spec is not acceptable.
• If you fail sterility test, you have to do thorough investigation on manufacturing process and test environment (not just the lab)

6. Analysis of a suppliers' Certificate of Analysis

Often the small users or laboratories do not make bacteriostatic water but purchase. In this case the COA is the main tool to show quality and must be reviewed:

• Does the COA shows lot number, same as on vial?
• All listed above release tests are present (method and acceptance criteria) not only 'complies'
• Numeric results are presented for pH, Benzyalcohol and endotoxin.
• Name of the lab that performed tests. (Independant lab with verifiable number for report would be good)
• Dates are consistent, test date is after manufacture and before expiry
• Authorized by someone with QA role (name) with sign and date.

Example: 1 lot, 4 separate reports

This is easy when the supplier has third party results posted for a specific lot. E.g. Herbilabs gets its reconstitution solution for research grade (bacteriostatic water 0.9% benzyl alcohol, vials 10ml) tested by the independent lab Janoshik Analytical. For batch BW25-1001 there are 4 public reports. The contents say:

Test (Janoshik report)	Results	Ref value	Assessment
Bacterial endotoxin (#77803, 11.09.2025)	0.131 EU/ml	<=0,25 (in-house) EU/ml, <=0.5 (pharma) EU/ml	Within limit. With margin
pH (#78663, 11.09.2025)	6.56	4.5-7.0	Within range
Benzyl alcohol (#77801, 12.09.2025)	8.53mg/ml	Label claim 9.0 mg/ml (0.9% w/v)	94.8% of label claim
Microbial Count (TAMC + TYMC) (#77802, 25.09.2025)	Pass / Pass	Pass	Complies

Check with the checklist.

• Traceability: They all 4 have the same batch number. Meaning that there is one lot.
•  Independence and Verification: Reports from a named external lab. The individual reports can be opened on the lab's site with task number.
• Numeric Results: Endotoxin/pH/Preservative quantity are numeric, not just "complies".
• Not Shown: TAMC/TYMC is a count of microbes. Not the pharmacopoeial test (Sterility) (USP <71>, Ph.Eur. 2.6.1). If you need information on sterility, ask for it. The reports do not name the method. (Ask for that to make a full review.)

 Regardless of which supplier. Ask for reports before first order. On receipt, link to the lot nr. and file.

7. Checklist to Release a Batch

Before release or acceptance, check:

• Have you checked the batch record? Is it complete? 
• Have all the deviations been addressed?
• Are the appearance, pH and fill volume within spec?
• Is the assay of benzyl alcohol within the spec range for label claim?
• Is the sterility test negative? 
• Are controls within spec for test environment?
• Is the bacterial endotoxin test within limits? 
• Is the method suitability valid?
• Is the sub-visible particle count within limits?
• Is there current evidence of CCI for the container/closure system?
• Are there AET data on file which are valid for the current formulation and pack?
• Does the label list the name and concentration of the preservative?
• Is the specific COA issued and signed for the lot?

Bacteriostatic water may seem like a commodity but the quality of the product is controlled by a few key factors. An endotoxin controlled and sterile product. A tested and proven effective preservative at the correct concentration. A container that closes after each use. A clear specification, the rigor of your OOS procedure and a lot specific COA allow these controls to become readily verifiable data that can be reviewed within minutes by a QC team, an auditor or customer.

References: 
1. USP-NF General Chapters <51>, <71>, <85>, <788>, <797>, <1207>. 
2. Bacteriostatic Water for Injection. European Pharmacopoeia 5.1.3, 2.6.1, 2.6.14. FDA. 
3. Guidance for Industry - Investigating Out-of-Specification Test Results for Pharmaceutical Production.